7MM obesity market to hit $173.5b sales by 2031

However, therapies remain limited due to high costs.

Obesity medication sales are projected to reach $173.5b in the seven major markets (7MM) by 2031, according to GlobalData.

The sector’s expansion is attributed to increasing patient awareness and growing physician adoption of pharmacotherapy.

However, therapies remain limited due to high costs, said Costanza Alciati, Pharma Analyst at GlobalData.

Over 200 million people currently live with obesity in 7MM, with these numbers rising at an annual growth rate of 0.7% during the forecast period.

“Many promising new drugs are expected to reach the market in the next few years. This will not only continue revolutionising the obesity space but also the whole cardiometabolic diseases sector,” Alciati added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan.